|
- 积分
- 244
- 威望
- 244
- 包包
- 616
|
本帖最后由 细胞海洋 于 2016-1-23 09:51 编辑 . s; g( M: F0 A1 Q! {
$ w, i# k; z8 X9 c5 f9 s! Y9 f目录
1 a/ ^9 u, O8 d- C4 z1 j$ s: A免疫治疗引领肿瘤治疗新模式 ...................................................................................................... 4
8 W1 L1 s8 @6 i1 M抗癌领域新突破 .................................................................................................................. 4
) q! c1 M$ a1 I0 u/ M600 亿美元市场空间 ............................................................................................................ 4
5 |. N# M: X& }; o( T% ]免疫检查点的突破——PD-1 ....................................................................................................... 5
/ l" Y- F% z& ~3 v+ hPD-1 单抗——肿瘤免疫治疗的明星 .......................................................................................... 5. \+ O, E; p( R
PD-1 重磅产品频出 ............................................................................................................. 5% n2 L/ y! ~& J$ B/ O
在研PD-1 单抗全面开花 ....................................................................................................... 6
8 ?' W/ i5 w. j2 xPD-1 临床试验数据——适应人群广泛，效果显著 .......................................................................... 7
) V1 m+ T# u6 N6 C1 Q4 ^5 kPD-1 以优秀的临床表现快速斩获非小细胞肺癌适应症 .................................................................... 9( Y" j7 F3 ?' I: q" {# y
PD-1 联用——免疫鸡尾酒疗法引爆行业增长点 ............................................................................ 9/ x$ o2 U6 z2 \, K" V8 G* x
PD-1 市场前景广阔 ........................................................................................................... 10
& n% I) R% K& v, W6 B免疫治疗热门靶点——PD-L1 ................................................................................................... 19
T- D# D8 W+ F+ G% [4 p- Z' v0 cPD-L1 单抗免疫疗法原理 .................................................................................................... 19, R7 T7 ^7 E. [; V2 j. u
PD-L1 单抗在研情况 .......................................................................................................... 19
, z( H- z: u. k+ F1 ^" q; B; lPD-L1 联用——多靶点治疗新选择 ......................................................................................... 19
+ Y! f( r* r7 F& U) D% G! J5 p3 GPD-L1 未来市场 ............................................................................................................... 20
5 f Q& d4 j& o* S. ~9 V z4 V8 y免疫治疗另一靶点——CTLA-4 .................................................................................................. 21) u% z1 g$ t3 z3 t0 V" s( C
CTLA-4 单抗免疫疗法原理 ................................................................................................... 21" S! @$ y1 x; P. t
CTLA-4 单抗已上市产品 ..................................................................................................... 21% W! k: l, q% S- [% N8 {* C
CTLA-4 在研产品.............................................................................................................. 22
+ @2 b2 l! X; y9 {1 P8 ACTLA-4 的未来，联合用药是出路 .......................................................................................... 23; \2 J$ r( v, R6 ]
相关公司简介 ........................................................................................................................ 24% w' o; D) v. i, p
君实生物 ........................................................................................................................ 24
+ o# w: l h# `7 q. V恒瑞医药（确信买入评级） .................................................................................................. 25; ]4 g+ i0 F0 @
百时美施贵宝（BMS） ....................................................................................................... 265 L; z% Y: W6 w8 H
默克（Merck） ................................................................................................................ 27
& }$ e ^5 i9 D, u( X- d# b, D& l3 p: E( J8 }4 P, c1 t% c
* T3 \1 \7 O1 S8 F0 I# V/ H
[hide][/hide] |
附件: 你需要登录才可以下载或查看附件。没有帐号？注册
-
总评分: 威望 + 10
包包 + 20
查看全部评分
|
发表于 2016-1-23 09:08
发表于 2016-1-23 19:55
